Nov 30, 2022

HC Andersen Capital Wed, Nov 30, 2022 08:20 CET QLIFE HOLDING – PRESENTATION OF Q3 INTERIM REPORT 2022 Qlife Holding has recently published their interim report for Q3 2022. Revenue in the period amounted to kSEK 1,967 (5,871). Revenue includes sales of Egoo.Health devices and capsules for the device. The company has continued decline in test activity following the end of Covid travel restrictions has led to a decline in revenue in line with expectations from the company. EBITDA for the period amounted to kSEK -14,850 (-12,146), and net loss kSEK -20,678 (-12,268). Qlife Holding AB is a med-tech group that strives to revolutionize the market for clinical biomarker and virus tests. By enabling tests at home as a complement to tests in healthcare, access to important health information is facilitated, which can contribute to better treatment and potentially prevent diseases. Qlife Holding was formed in October 2019 and received the certification ISO 13485:2016 the same year, which means that Qlife meets all requirements for the manufacture and sale of in-vitro diagnostic analyzers and reagents. The first capsules in the company's product, Egoo.Health Platform, was CE marked for professional use in early 2020. The company has patent protection for key parts of its technology. Meet Qlife Holding’s CEO Thomas Warthoe and CFO Kasper Rousøe when they present the Q3 report. Wednesday November 30, 13:00-13:30 ------------------------------------------- Disclaimer: HC Andersen Capital receives payment from the companies mentioned for a DigitalIR/Corporate Visibility agreement. The content is not buy or sell recommendations. Mie Halse mie@hcandersencapital.dk +45 28746640 #DigitalIR is the digitalization of the relationship between investors and stock-listed companies. #DemocraticIR is the basic idea that all investors should have access to equal information.